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We present a method for testing overrepresentation of biological pathways, indexed by gene-ontology terms, in lists of signiﬁcant SNPs
from genome-wide association studies. This method corrects for linkage disequilibrium between SNPs, variable gene size, and multiple
testing of nonindependent pathways. Themethodwas applied to theWellcome Trust Case-Control ConsortiumCrohn disease (CD) data
set. At a general level, the biological basis of CD is relatively well known for a complex genetic trait, and it thus acted as a test of the
method. The method, known as ALIGATOR (Association LIst Go AnnoTatOR), successfully detected biological pathways implicated
in CD. Themethod was also applied to ameta-analysis of bipolar disorder, and it implicated themodulation of transcription and cellular
activity, including that which occurs via hormonal action, as an important player in pathogenesis.Introduction
Genome-wide association (GWA) analysis can be a power-
ful method for identifying genes involved in complex
disorders, which often arise from the interplay of multiple
genetic and environmental risk factors.1
The GWA approach has proven to be successful in iden-
tifying susceptibility genes for several complex disorders2–4
on the basis of identiﬁcation and replication of associated
SNPs. It seems intuitively likely that susceptibility alleles
for any given disorder are not randomly distributed among
genes but, instead, are distributed among one (or more)
set(s) of genes whose functions are to some extent related.
Under such a model, although a number of SNPs would be
expected to show modest association when analyzed in
isolation, one would expect to see an overall excess of
SNPs with moderate p values for association on a list of
SNPs representing a set of genes from relevant related bio-
logical pathways.
Several methods exist for prioritizing gene pathways for
involvement in disease susceptibility, based on functional
annotation,5 gene-expression data,6 sequence features,7
protein-protein interactions,8 or a combination ofmultiple
types of data.9 Recently, pathway-based approaches have
been developed for application to the results of genome-
wide linkage10 and association11 studies.
This paper presents a novel method, called ALIGATOR
(Association LIst Go AnnoTatOR), for studying groups of
genes by testing for overrepresentation of members of
those groups within lists of genes containing signiﬁcantly
associated SNPs from GWA studies. The aim is to identify
whether certain groups of genes are potentially diseasecausing. To illustrate the application of the method, we
deﬁned groups on the basis of membership in Gene
Ontology (GO) database categories, though the approach
is applicable to any other gene-membership classiﬁcation
system. Compared with single-locus analysis, group or
pathway analysis may yield more secure insights into
disease biology, because an associated pathway is likely
to implicate function better than a hit in a single gene
that may have many functional possibilities. Additionally,
genetic heterogeneity may cause any one causal variant to
exhibit only modest disease risk in the sample as a whole,
because different individuals may possess different disease-
risk alleles at different loci in the same gene or in different
genes. This will reduce the power to detect any one variant
by traditional association methods. However, if the genes
in question are members of the same biological pathway,
then considering the pathway as the unit of analysis may
increase the power to detect association between the genes
and disease. For similar reasons, association of disease with
biological pathways may be easier to replicate across
different studies than association to individual SNPs or
genes. This approach can be regarded as complementary
to the studies that focus on the top hits.
In our method, we deﬁne a list of signiﬁcant SNPs,
applying an arbitrary threshold of signiﬁcance to the
GWA study, and test for overrepresentation of categories
of genes, deﬁned by GO terms (henceforth referred to as
GO categories) on this list. Our analysis method corrects
for the presence of linkage disequilibrium (LD) between
SNPs, variable gene size, overlapping genes, and multiple
nonindependent GO categories. It can be applied to data
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We apply our approach to the Wellcome Trust Case-
Control Consortium (WTCCC) Crohn disease (CD) GWA
data set. At a general level, the biological basis of CD is rela-
tively well known for a complex genetic trait, so it can be
regarded as a proof-of-principle test of themethod. In addi-
tion, we apply our method to a meta-analysis of bipolar
disorder (BD) GWA study data sets (including the WTCCC
data set), for which imputed data are available. This en-
ables us to investigate the improvements provided by
a larger sample size and the increased gene coverage given
by the imputed data.
Material and Methods
GO Categories
The GO database12 assigns biological descriptors (GO terms) to
genes on the basis of the properties of their encoded products.
These terms fall into three types: cellular component, biological
process, and molecular function. Genes assigned the same GO
term can thus be regarded as members of a category (‘‘GO cate-
gory’’) of genes that are more closely related in terms of some
aspect of their biology than are random sets of genes. Rather
than restricting analysis to categories at an arbitrarily deﬁned level
in the GO hierarchy, we chose to analyze all GO categories con-
taining at least three genes.
SNP ID and Chromosomal Location
The ‘‘dbSNP chromosome report’’ ﬁle, based on human genome
assembly build 36.2, was downloaded from the NCBI ftp site for
chromosomes 1–22 and X. From this ﬁle, the following three
data ﬁelds were extracted for reference sequence entries only: rs#
(SNP rs number), chr (chromosome), and chr pos (chromosome
position).
Assigning SNPs to Genes and Gene Regions
The ‘‘seq-gene’’ ﬁle was downloaded from the NCBI ftp website.
First, for the exclusion of pseudogenes, records with a ‘‘feature_id’’
of ‘‘pseudo’’ were removed. All records with a ‘‘feature_type’’ of
‘‘gene,’’ ‘‘group_label’’ of ‘‘reference,’’ and ‘‘tax_id’’ of ‘‘9606’’
(i.e., human) were extracted. The following four ﬁelds were re-
tained: chromosome, chr_start, chr_stop, and feature_id (NCBI
gene ID).
The extracted SNP ID and chromosomal location ﬁle was
compared to this ﬁle, ﬁrst by chromosome and second by position.
Output ﬁles were generated, containing SNP rs numbers and the
gene region(s) in which those SNPs lie. We generated two such
output ﬁles. The ﬁrst comprised SNPs assigned to genes on the
basis of being located within the genomic sequence corresponding
to the start of the ﬁrst and the end of the last exon. For the second,
we added SNPs within 20 kb of the 50 and 30 ends of the ﬁrst and
last exons, respectively. The choice of 20 kb has been used by us
elsewhere for candidate gene analysis13 to capture proximal regu-
latory and other functional regions that may lie outside, but close
to, the gene. If a SNP was found to be located within more than
one gene or gene region, all entries were included.
Assigning GO Terms to Genes and Gene Regions
Subsequently, the GO categories associated with these genes were
obtained by linking the gene Locus ID to GO categories with the14 The American Journal of Human Genetics 85, 13–24, July 10, 20use of the gene2go ﬁle available as part of the NCBI Entrez Gene
database. More information on the gene2go ﬁle can be obtained
from the readme ﬁle (see Web Resources). The gene2go ﬁle was
generated with data from the Gene Ontology Annotation (GOA)
database.14
This ﬁle gives a list of genes (indexed by EntrezGene ID) and GO
categories of which each gene is a member. For each GO category
listed in gene2go, the complete set of categories of which that cate-
gory is a subset was obtained by recursive examination of the
ontology ﬁle from the AmiGO website.
This set of categories was added to those already present in gen-
e2go, producing a complete list of GO category memberships for
each gene.
Platform SNP Lists
We used NCBI SNP lists based upon build 36.2. The annotations of
SNPs present on the genotyping platforms were updated as neces-
sary. Newly assigned SNP rs ID numbers were obtained with the
NCBI SNP batch entry list (see Web Resources).
Statistical Analysis Method
The presence of LD between SNPs complicates analysis, as does
variable gene size and number of SNPs per gene.We chose to prese-
lect a p value criterion to deﬁne a list of signiﬁcantly associated
SNPs. These SNPs deﬁne a list of signiﬁcantly associated genes,
each gene counted only once regardless of the number of signiﬁ-
cantly associated SNPs that it contains. The number of signiﬁ-
cantly associated genes in each GO category can be counted. Anal-
ysis was restricted to categories containing at least two signiﬁcant
genes, in order to prevent small categories appearing to be signif-
icantly overrepresented on the basis of one (possibly chance) hit.
This approach is simple, and it can be applied regardless of the LD
relationships between the SNPs. However, the number of signiﬁ-
cantly associated genes in each category will not follow a standard
distribution (such as the hypergeometric distribution), because
the probability that a gene appears on the list will depend on
the number of (effectively independent) SNPs that it contains. The
more (effectively independent) SNPs that a gene contains, the
more likely that at least one SNP, and therefore that gene, will be
considered ‘‘signiﬁcant.’’ Therefore, the signiﬁcance of the
number of signiﬁcantly associated genes in each category was as-
sessed by simulations, as follows: SNPs were drawn successively
at random from the set of all SNPs used in the study, and the genes
that contained that particular SNP were added to the list of signif-
icant genes. The process was repeated until the list of signiﬁcant
genes was the same length as that in the original study. Five
thousand replicate gene lists were generated in this way,
enabling empirical p values to be calculated for the number
of signiﬁcantly associated genes in each GO category (i.e., the
proportion of replicate gene lists containing at least as many
genes from that GO category as the original list). This proce-
dure implicitly assumes that the level of LD between SNPs is
approximately equal across GO categories; violations of that
assumption will lead to test statistics that are overconservative
for categories in which the average LD between SNPs within
member genes is higher than the genome-wide average. This
is because in contrast to the real data set, under the simulation
procedure, the probability of selecting a gene to the list by
chance is proportional to the number of SNPs in that gene,
not the effective number of independent SNPs15 that the
gene contains. For genes with several SNPs in high LD, the09
effective number of independent SNPs is much smaller than
the total number of SNPs, so the probability that they are
selected to the simulated gene lists is inﬂated relative to the
actual data set, thereby reducing the signiﬁcance of observing
them on the original list. Ideally, one would like to perform
replicates of the GWA study by permuting disease status, rank
the SNPs from each replicate study in order of signiﬁcance,
and use these to generate gene lists. However, as noted,11 this
is computationally intensive. Furthermore, permutation requires
access to the individual genotype data, which may not always
be available.
Correction for Multiple Testing
In an experiment of this nature, several GO categories will gener-
ally be tested simultaneously. It is therefore desirable to correct the
individual category-speciﬁc p values for the number of categories
being tested. Because the categories are not independent, standard
methods, such as the Bonferroni and Sidak corrections, are inap-
propriate, as is the use of false discovery rate (FDR) procedures.
We corrected for multiple testing by using a bootstrap approach.
One of the 5000 replicate gene lists was selected at random to be
the ‘‘observed data.’’ A sample of 5000 gene lists for assessing
signiﬁcance was generated by random sampling with replacement
(thus, lists could be counted once, more than once, or not at all)
from the remaining gene lists. p values for the number of signiﬁ-
cantly associated genes in each GO category in the ‘‘observed
data’’ were calculated as before. This procedure was repeated
1000 times. Each p value from the original data can thus be cor-
rected for testing multiple categories, the corrected p value being
the proportion of bootstrap replicates for which the minimum
p value across all categories is less than or equal to the category-
speciﬁc p value from the original data. The ‘‘expected number of
hits’’ for each category can be calculated as the average number
of categories per bootstrap replicate with p values less than or
equal to the (uncorrected) p value from the original data. Finally,
the number of categories with p values less than a given value
Figure 1. Flow Diagram Showing the
Procedure for Estimating Statistical
Significance
(0.05, 0.01, 0.001) in the original data
can be compared with the corresponding
values from the bootstrap replicates. An
excess of signiﬁcantly overrepresented
GO categories suggests a nonrandom
distribution of associations and thus
provides support for a biological basis for
the disease. A ﬂow diagram of the method
used for assessing statistical signiﬁcance is
given in Figure 1.
Application to Data
As a ‘‘proof of principle,’’ the method was
applied to the results of the WTCCC CD
case-control study, which, for a complex
disease, is relatively well characterized
and is thus a reasonable test of the effec-
tiveness of the method. The method was
also applied to the data from a meta-anal-
ysis of BD genome scans. BD is a disorder whose biological back-
ground is not well characterized, so the results of the analysis are
of considerable interest.
The summary statistics for the CD study were downloaded from
the WTCCC website. These data were produced from an analysis
of 1748 cases versus 2953 controls, based upon the Affymetrix
500K Chip. After quality control procedures, the WTCCC retained
genotypes on 469,557 SNPs (for more details, see the WTCCC
article2), of which 181,961 lay within genes, covering 14,653
genes and 4685 GO categories. A total of 246,929 SNPs lay within
20 kb of a gene, covering 22,253 genes and 5177 GO categories.
Extending the region within which a SNP is considered to map
to a gene considerably increases the coverage of genes, although
it is unknown a priori whether this increases or decreases the ratio
of signal to noise. SNPs were deﬁned as ‘‘signiﬁcantly associated’’ if
the Armitage Trend test had a p value of 13 104 or less. This is the
criterion used by the WTCCC to deﬁne the SNPs of interest that
were listed in their Supplemental Data. Less stringent criteria of
p < 0.001 and p < 0.005 were also explored. These criteria were
met by 308, 1226, and 3905 SNPs lying within 74, 253, and 833
genes, respectively. As mentioned previously, GO categories con-
taining only one signiﬁcant gene were not counted as overrepre-
sented, because a single chance association in a small GO category
could result in that category having false evidence of overrepresen-
tation.
Data were also analyzed from ameta-analysis of theWTCCC BD
sample together with BD samples from the United States (STEP-BD
collection), University College London, and the Universities of
Edinburgh and Dublin,16 consisting of a total of 4387 cases and
6209 controls. There were 325,690 SNPs genotyped in common
between the samples and met quality control thresholds in each
of the studies. Of these, 123,840 lay within genes, covering
13,204 genes and 4487 GO categories. Data were imputed for
HapMap SNPs (for details, see Ferreira et al.16), giving a total set
of 1,769,948 SNPs. Of these, 679,901 lay within a total of 17,249
genes and 4877 GO categories. Not surprisingly, imputed SNP
data greatly enhanced gene coverage as compared to arrayThe American Journal of Human Genetics 85, 13–24, July 10, 2009 15
Table 1. Number of Significantly Overrepresented GO Categories: CD Data Set
p < 0.05 p < 0.01 p < 0.001
p Value Criterion for
SNPs No. of Top SNPs No. of Genes No. of Categories p Value No. of Categories p Value No. of Categories p Value
0.0001 308 74 55 0.091 32 0.009 17 0.001
0.001 1226 253 72 0.275 35 0.018 7 0.054
0.005 3905 833 124 0.151 35 0.088 9 0.032
Number of GO categories reaching various levels of significance for overrepresentation on the list of significant SNPs in the WTCCC CD data set and their corre-
sponding genes, together with p values indicating whether this number is significantly greater than that expected by chance. Only categories containing two or
more significant genes are counted. SNPs assigned to genes if they lie within that gene. Genotyped SNPs only.genotypes alone, so these data were chosen for the main analysis
presented in this paper. There were 593, 3759, and 15,979 SNPs
that were signiﬁcant at p < 1 3 104, p < 0.001, and p < 0.005,
lying within 50 genes, 296 genes, and 1036 genes, respectively.
Analysis of CD with the LD-Pruned SNP Set
An LD-pruned SNP set was obtained for theWTCCCCDdata set as
follows: At each step, the SNP with the most signiﬁcant p value
was selected, and all SNPs within 1Mb with r2> 0.2 were removed
(both criteria that we accept are arbitrary). Then, the most signif-
icant of the remaining SNPs was selected, and the process was
repeated until no pair of SNPs within 1 Mb of each other and
with r2 > 0.2 remained. This left 61,246 SNPs within genes,
covering 12,899 genes (compared to 14,653 covered by the
complete SNP list). The number of SNPs with p < 0.0001, p <
0.001, or p < 0.005 in each category was counted (counting
multiple signiﬁcant SNPs in the same gene separately), as was
the total number of signiﬁcant SNPs overall. Replicate lists of
signiﬁcant SNPs of the same length as the original list were gener-
ated by randomly sampling SNPs (assuming independence). The
numbers of signiﬁcant SNPs in each GO category in each replicate
list were obtained, and these were used to obtain category-speciﬁc
p values for overrepresentation. The same bootstrap technique as
that described in the main manuscript was used for assessing
whether there was an excess of signiﬁcantly overrepresented cate-
gories.
This method counts multiple hits from the same gene, which
may increase power. However, there is also the question of where
to set the r2 cutoff for deﬁning pairs of SNPs in LD—low values will
result in a sparse map of SNPs, which may lose power as a result of
reduced gene coverage, whereas if higher values are used, multiple
signals in a gene may have considerable interdependence due to
LD. This would result in false positives if the signals are analyzed
under the assumption that the markers are independent.
Results
The number of categories reaching uncorrected category-
speciﬁc signiﬁcance levels of 0.05, 0.01, and 0.001 for over-
representation in the WTCCC CD data set, when analysis
was restricted to SNPs lying within genes, is shown in
Table 1. We also tested whether the total number of over-
represented categories was signiﬁcantly in excess as com-
pared with the null expectation. For CD, the signiﬁcance
of the excess of overrepresented categories increased with
the stringency of the signiﬁcance criterion deﬁning over-
representation. The signiﬁcance of the number of overrep-16 The American Journal of Human Genetics 85, 13–24, July 10, 20resented categories also increased as the p value cutoff for
deﬁning signiﬁcant SNPs became more stringent. This
suggests that associations for CD are concentrated in a rela-
tively small number of categories, each of which shows
strong evidence of overrepresentation.
The most signiﬁcant individual categories, with a cutoff
of p < 1 3 104 used for deﬁning signiﬁcant SNPs, are
shown in Table 2, and complete category-speciﬁc results
are presented in Table S1 (available online). We also
present (as expected hits per study) the number of cate-
gories expected by chance to have a category-speciﬁc
p value at least as signiﬁcant as that of the test category,
thus giving a measure of signiﬁcance allowing for multiple
testing of categories. Note that, for categories with a cate-
gory-speciﬁc p value of 0, a smaller value of expected hits
per study may be obtained by simulating more than
5000 replicate gene lists.
The overrepresented categories for CD include those
related to the major histocompatibility complex (MHC),
immunological response, and antigen processing. The in-
volvement of MHC in the genetic etiology of CD is well
known.17,18 Likewise, immunological response andantigen
processing are well-established features of this disease.19
Although these results are not novel, they provide a proof
of principle of the effectiveness of the method. The list of
categories for CD also contains several relating to ubiquiti-
nation, one of the twomajor intracellular protein-degrada-
tion systems—the other being autophagy (a catabolic
process that involves delivery of cellular components to
the lysosome for degradation). GWA studies have already
implicated autophagy as an important functional pathway
involved in CD,20 although we did not ﬁnd exidence for
overrepresentation of GO categories involving autophagy
here. There are seven genes with SNPs signiﬁcant at p <
13104 inoneormoreof the fourubiquitinationcategories
shown in Table 3 (GO: 6511, 6512, 4221, and 4383): CYLD
(MIM 605018), USP4 (MIM 603486), RNF123, CUL2 (MIM
603135), KLHL20, USP7 (MIM 602519), and FAF1 (MIM
604460). CYLD is approximately 90 kb from NOD2
(MIM 605956), and its apparent association could be due
to LD with NOD2. USP4 and RNF123 are in the previously
published 3p21 locus.21 A nonsynonymous SNP in MST1
(MIM 142408) has been postulated as responsible for the
association at this locus.22 However, neither USP4 nor09









of Genes on List p Value
Expected
Hits per Study Function
GO02504 PROCESS 11 2 0.02 0.0000 0.32 antigen processing and presentation of
peptide or polysaccharide antigen via MHC
class II
GO32395 FUNCTION 9 2 0.01 0.0000 0.32 MHC class II receptor activity
GO42613 CELLULAR 10 2 0.02 0.0000 0.32 MHC class II protein complex
GO06955 PROCESS 365 7 1.21 0.0002 0.54 immunological response
GO42611 CELLULAR 20 2 0.03 0.0002 0.54 MHC protein complex
GO51184 FUNCTION 9 2 0.04 0.0004 0.77 cofactor transporter activity
GO51181 PROCESS 8 2 0.02 0.0004 0.77 cofactor transport
GO51183 FUNCTION 8 2 0.03 0.0004 0.77 vitamin transporter activity
GO15226 FUNCTION 3 2 0.02 0.0004 0.77 carnitine transporter activity
GO15879 PROCESS 3 2 0.02 0.0004 0.77 carnitine transport
GO02376 PROCESS 492 8 1.95 0.0006 0.98 immune system process
GO06511 PROCESS 143 5 0.59 0.0006 0.98 ubiquitin-dependent protein catabolic
process
GO19941 PROCESS 143 5 0.59 0.0006 0.98 modiﬁcation-dependent protein catabolic
process
GO43632 PROCESS 143 5 0.59 0.0006 0.98 modiﬁcation-dependent macromolecule
catabolic process
GO51603 PROCESS 144 5 0.59 0.0006 0.98 proteolysis involved in cellular protein
catabolic process
GO44257 PROCESS 146 5 0.6 0.0006 0.98 cellular protein catabolic process
GO19882 PROCESS 34 2 0.07 0.0010 1.41 antigen processing and presentation
GO30163 PROCESS 178 5 0.71 0.0012 1.6 protein catabolic process
GO04221 FUNCTION 53 3 0.18 0.0012 1.6 ubiquitin thiolesterase activity
GO04843 FUNCTION 56 3 0.19 0.0012 1.6 ubiquitin-speciﬁc protease activity
GO19783 FUNCTION 57 3 0.19 0.0012 1.6 small conjugating protein-speciﬁc protease
activity
GO44265 PROCESS 244 5 0.91 0.0014 1.79 cellular macromolecule catabolic process
GO51180 PROCESS 11 2 0.06 0.0014 1.79 vitamin transport
GO16790 FUNCTION 66 3 0.22 0.0018 2.14 thiolester hydrolase activity
GO43285 PROCESS 241 5 0.9 0.0024 2.73 biopolymer catabolic process
GO07249 PROCESS 31 2 0.08 0.0028 3.11 I-kappaB kinase/NF-kappaB cascade
GO09057 PROCESS 292 5 1.06 0.0038 3.95 macromolecule catabolic process
GO06952 PROCESS 324 5 1.17 0.0044 4.42 defense response
GO06512 PROCESS 384 6 1.6 0.0048 4.73 ubiquitin cycle
GO44248 PROCESS 440 6 1.64 0.0054 5.19 cellular catabolic process
List of 30 most significantly overrepresented GO categories for CD (cutoff for significant SNPs: p < 1 3 104). The type of category and the expected number of
categories with a category-specific overrepresentation p value at least as significant as that observed in the absence of any true overrepresentation are also shown.RNF123 were genotyped, so their association with CD risk
cannot be deﬁnitively excluded.CUL2 is in a ‘‘newly identi-
ﬁed’’ locus on chromosome 10p11 showing convincing
evidence for association in a large meta-analysis of GWA
data.21 FAF1 (TNFRSF6 associated factor) is a particularly
interesting candidate for involvement in CD susceptibility,Thbecause it shows evidence of association in both the
WTCCC study2 (p ¼ 1.6 3 105) and the meta-analysis21
(p¼ 13 104). Furthermore, it is well established as a nega-
tive regulatorofNFkappaB,which is a keyplayer in thepath-
ogenesis of CD. There is also prior evidence linking ubiqui-
tination with CD.23,24 Thus, the role of ubiquitination ine American Journal of Human Genetics 85, 13–24, July 10, 2009 17
Table 3. Number of significantly Overrepresented GO Categories: BD Meta-Analysis Data Set
p < 0.05 p < 0.01 p < 0.001
p Value Criterion for SNPs No. of Top SNPs No. of Genes No. of Categories p Value No. of Categories p Value No. of Categories p Value
0.0001 593 50 21 0.556 6 0.521 2 0.246
0.001 3759 296 61 0.546 17 0.363 3 0.301
0.005 15979 1036 133 0.112 46 0.017 13 0.009
0.01 29073 1698 232 0.001 74 0.001 22 <0.001
Number of GO categories reaching various levels of significance for overrepresentation on the list of significant SNPs in the BD meta-analysis data set and their
corresponding genes, together with p values indicating whether this number is significantly greater than that expected by chance. Only categories containing two
or more significant genes are counted. SNPs assigned to genes if they lie within that gene. Genotyped and imputed SNPs.CD isworthy of further study.Of further substantial interest
is category 6955 (‘‘immune response’’). This category
contains seven genes with SNPs signiﬁcant at p < 1 3
104 (category-speciﬁc p ¼ 0.0002 for overrepresentation).
These genes include NOD2, IL23R (MIM 607562), and
TNFSF15 (MIM 604052), all of which were identiﬁed as
putative susceptibility genes for CD in a recent review20
and showed convincing evidence for association in the
meta-analysis.21 The other four genes are SBNO2, CCL18
(MIM 603757), HLA-DQA2, and HLA-DQB2. These, and
other genes in the category, may be interesting additional
candidates for involvement in CD susceptibility.
The analysis method assumes that the probability that
a gene is present on the list of signiﬁcant genes is indepen-
dent of the presence or absence of other genes in that list—
in other words, that SNPs from different genes are not in
LD. Although this is often a reasonable assumption, there
are regions of the genome in which long-range LD is
known to exist. One of these is the MHC region, located
at chromosome 6p21.3, which is known to be implicated
in autoimmune diseases such as CD. It is possible that
the overrepresentation of signiﬁcant categories in Table 1
could be due to hits in multiple genes from the MHC
region and that these may be due to LD, rather than to
several different genes being involved in disease etiology.
To investigate this possibility, we reran the analysis, omit-
ting all genes and SNPs in theMHC region, deﬁned25 as the
region between HLA-F (MIM 143110) and KIFC1 (MIM
603763). For a cutoff of p < 1 3 104 for deﬁning signiﬁ-
cant SNPs, this resulted in 26 categories reaching a signiﬁ-
cance level of 0.01 for overrepresentation and 15 reaching
a signiﬁcance level of 0.001. These are both signiﬁcantly
higher than would be expected by chance (p ¼ 0.032 and
0.003, respectively).
Thus, there is still a signiﬁcant excess of overrepresented
categories for CD, even after removal of the MHC region,
suggesting that most of the overrepresented categories in
Table 2 do not depend on multiple MHC genes. The
most signiﬁcantly overrepresented categories after removal
of the MHC region are shown in Table S3. As expected,
categories containing several genes from the MHC region,
such as those involving immunological response or MHC
activity, are no longer signiﬁcant. Conversely, the promi-18 The American Journal of Human Genetics 85, 13–24, July 10, 200nence of categories related to ubiquitin (as noted earlier),
as well as to carnitine transport, is enhanced. There is prior
evidence from different sources that suggests that variants
in the carnitine transporter genes SLC22A4 (MIM 604190)
and SLC22A5 (MIM 603377) are associated with CD.26
Using a 20 kb window for assigning SNPs to genes re-
sulted in similar categories being highlighted, although
the signiﬁcance of the number of overrepresented cate-
gories was reduced (see Table S4).
The number of categories reaching signiﬁcance levels for
overrepresentation of 0.05, 0.01, and 0.001 in the BD
meta-analysis data set are shown in Table 3. Imputed
SNPs were used, as well as SNPs that were assigned to genes
if they lay within that gene (no window). The signiﬁcance
of the number of overrepresented categories increased as
less stringent criteria were used in deﬁning signiﬁcant
SNPs. In particular, the most signiﬁcant results were ob-
tained with a cutoff of p < 0.01. This suggests that,
compared to CD, the genetic susceptibility to BD (at least
as currently deﬁned) may involve risk alleles with smaller
individual effects.27
Given that this level of stringency resulted in the
maximum enrichment for signiﬁcant pathways, we used
the threshold of p < 0.01 to examine speciﬁc associated
pathways. The results are shown in Table 4, the full list
of which is shown in Table S2. Many of the overrepre-
sented GO categories implicate biological systems involved
in the broad control of cellular activity, including the cate-
gories of hormone activity, RNA splicing, and macroau-
tophagy. Autophagy is a catabolic process that is crucial
to normal cell growth, development, and homeostasis,
and it is known that lithium, the major prophylactic medi-
cation for BD, can induce autophagy.28 Within the cate-
gory of hormone activity, both the genes encoding thyro-
tropin-releasing hormone (TRH [MIM 275120]) and those
encoding thyroglobulin (TG [MIM 188450]) were identi-
ﬁed. Both are involved in thyroid function, which modu-
lates cellular activity, is known to inﬂuence mood in
general29 and BD in particular,30 and is inﬂuenced by
lithium.31 Also within the category of hormone activity
is the gene encoding proopiomelanocortin preproprotein
(POMC [MIM 176830]), whose protein product, adrenocor-
ticotrophin, is essential for normal functioning of the9









of Genes on List p Value
Expected Hits
per Study Function
GO05179 FUNCTION 75 10 2.83 0.0000 0.57 hormone activity
GO03700 FUNCTION 692 88 64.03 0.0000 0.57 transcription factor activity
GO16236 PROCESS 7 3 0.24 0.0000 0.57 macroautophagy
GO30212 PROCESS 6 5 0.43 0.0000 0.57 hyaluronan metabolic process
GO00045 PROCESS 6 3 0.24 0.0000 0.57 autophagic vacuole formation
GO03677 FUNCTION 1776 189 148.04 0.0002 0.9 DNA binding
GO03676 FUNCTION 2550 259 215.15 0.0002 0.9 nucleic acid binding
GO33077 PROCESS 6 3 0.25 0.0002 0.9 T cell differentiation in the thymus
GO08380 PROCESS 181 23 10.74 0.0002 0.9 RNA splicing
GO06323 PROCESS 75 12 3.68 0.0002 0.9 DNA packaging
GO42301 FUNCTION 6 3 0.3 0.0002 0.9 phosphate binding
GO06465 PROCESS 7 4 0.6 0.0002 0.9 signal peptide processing
GO04867 FUNCTION 81 17 7.24 0.0004 1.26 serine-type endopeptidase inhibitor activity
GO05102 FUNCTION 572 74 53.92 0.0004 1.26 receptor binding
GO33151 PROCESS 5 3 0.26 0.0004 1.26 V(D)J recombination
GO06623 PROCESS 3 2 0.21 0.0004 1.26 protein targeting to vacuole
GO07034 PROCESS 18 7 1.95 0.0006 1.63 vacuolar transport
GO00398 PROCESS 57 9 2.58 0.0008 2.01 nuclear mRNA splicing, via spliceosome
GO00377 PROCESS 57 9 2.58 0.0008 2.01 RNA splicing, via transesteriﬁcation
reactions with bulged adenosine as
nucleophile
GO00375 PROCESS 57 9 2.58 0.0008 2.01 RNA splicing, via transesteriﬁcation reactions
GO30528 FUNCTION 1066 128 101.76 0.0010 2.41 transcription regulator activity
GO18345 PROCESS 4 3 0.3 0.0010 2.41 protein palmitoylation
GO05634 CELLULAR 3617 372 328.82 0.0014 3.22 nucleus
GO44249 PROCESS 602 70 51.32 0.0014 3.22 cellular biosynthetic process
GO02521 PROCESS 51 10 4.06 0.0016 3.6 leukocyte differentiation
GO30098 PROCESS 39 9 3.2 0.0018 4 lymphocyte differentiation
GO05853 CELLULAR 5 2 0.07 0.0018 4 eukaryotic translation elongation factor 1
complex
GO04364 FUNCTION 16 4 0.5 0.0018 4 glutathione transferase activity
GO01958 PROCESS 3 3 0.46 0.0024 5.22 endochondral ossiﬁcation
GO07076 PROCESS 15 5 1.12 0.0028 6.02 mitotic chromosome condensation
List of 30 most significant GO categories for BD in the BD meta-analysis data set (cutoff for significant SNPs: p < 0.01). Genotyped and imputed SNPs used, with
SNPs assigned to genes if they lie within that gene. The type of category and the expected number of categories with a category-specific overrepresentation p
value at least as significant as that observed in the absence of any true overrepresentation are also shown.hypothalamic-pituitary-adrenal (HPA) axis, which, like
thyroid function, inﬂuences cellular activity. HPA dysfunc-
tion is known to be associated with mood disorders,
including BD.32 Genes implicated within the category of
RNA splicing include several members of the spliceosome
C complex, including small nuclear ribonucleoprotein
200kDa (U5) (SNRNP2000 [MIM 601664]), heterogeneous
nuclear ribonucleoprotein C (HNRPC [MIM 164020]),Thmago-nashi homolog (MAGOH [MIM 602603]), pre-
mRNA processing factor 6 homolog (PRPF6), and small
nuclear ribonucleoprotein 40kDa (U5) (SNRNP40 [MIM
607797]). This complex plays a major role in RNA splicing
and, hence, regulation, of cellular activity.33 This category
also includes A2BP1 (MIM 605104), a gene that encodes
ataxin 2 binding protein, which showed a strong associa-
tion signal in a recent GWA study of schizoaffectivee American Journal of Human Genetics 85, 13–24, July 10, 2009 19
disorder, bipolar type,34 and QKI (MIM 605950), which
encodes quaking homolog, a protein that is important
for normal myelination and is implicated in human
diseases, including schizophrenia.35
The signiﬁcance of the number of overrepresented cate-
gories ascertained on the basis of the analysis of the LD-
pruned data set, with multiple independent hits per gene
allowed, is given in Table S8, and the 30 most signiﬁcant
categories, with a cutoff of p < 0.0001 used for deﬁning
signiﬁcant SNPs, are given in Table S9.
If Table S8 is compared to Table 1, it can be seen that using
a cutoff ofp<0.0001 todeﬁne signiﬁcantSNPs still gives the
greatest excess of signiﬁcantly overrepresented categories
and that this excess has similar signiﬁcance to that obtained
when all SNPs are used but each gene is counted only once.
The less-stringent cutoffs give less signiﬁcant excess of over-
represented categories, and these are less signiﬁcant than
thecorrespondingvalues inTable1.Thus, allowingmultiple
independenthits per genedoesnot increase the signiﬁcance
of the resultshere. Themost signiﬁcant categories, shown in
Table S9, are also very similar to those in Table 2.
Discussion
We present a novel method for testing for overrepresenta-
tion of biological pathways among signiﬁcant SNPs from
GWA study data sets. Unlike previous approaches, our
method corrects for varying numbers of SNPs per gene and
multiple overlapping pathways. In addition to providing
a measure of signiﬁcance (corrected for multiple-testing)
for individual pathways, the method also assesses whether
the number of overrepresented pathways is signiﬁcantly
higher than expected (given the overlap between path-
ways), thus giving a measure of the overall signiﬁcance of
the list of associated genes. When applied to GWA data of
CD, a disease with a relatively well-characterized biological
background, the method identiﬁed several biological path-
ways known to be implicated in the disease etiology, thus
demonstrating its validity for providing insights into the
biological basis of complex diseases. Moreover, when we
applied themethodtoGWAdata fromtheBDmeta-analysis,
we identiﬁed a number of processes consistent with pre-
vious hypotheses concerning the etiology of this disorder,
although none of those has the degree of prior empirical
support equivalent to that of the involvement of the immu-
nological system inCD. Analyses of additional data sets will
be required for conﬁrmation of which of these speciﬁc
pathways are genuinely involved in disease.
The understanding of BD is much less advanced than
that of CD. There are no laboratory tests for BD as of yet,
and diagnoses are based on clinical features.36 To date,
the strongest signals that have emerged from a meta-anal-
ysis of published GWA studies of BD16 have implicated
genes whose products are involved in ion channel activity
(and, hence, control of neuronal excitability), including
ANK3 (MIM 600465) and CACNA1C (MIM 114205). The20 The American Journal of Human Genetics 85, 13–24, July 10, 200ﬁndings from our current analysis (which uses the same
combined data set) implicates several GO categories that
suggest that some aspects of the broad control of cellular
activity may also be important players in the pathogenesis
of BD, including the categories of hormone activity, RNA
splicing, and macroautophagy. At an intuitive level, there
is plausible face validity to the possibility that some aspects
of the broad control of cellular activity could inﬂuence the
BD phenotype: BD is an episodic disorder that is affected
by environmental changes, and, at least at a simplistic
explanatory level, both hyper- and hypoenergized states
can occur with reversion to periods of normal function
between acute episodes. It is well known that episodes of
BD can be precipitated by stressors, natural hormonal
changes, and administration of steroid medication,36 and
changes in transcriptional activity are a key mechanism
by which such stimuli interact with genotype to inﬂuence
phenotype. If this ﬁnding is replicated in other data sets, it
will be important to reﬁne observations to identify (1) the
most important biological systems affected by the general
transcriptional changes and (2) the extent to which the
ﬁndings may contribute to the genetic overlap between
schizophrenia and BD.37,38
A limitation of themethod is the requirement for speciﬁ-
cation of a p value cutoff in deﬁning the list of signiﬁcantly
associated SNPs, an approach similar to that taken by
programs, such as GO-stat,39 that analyze lists of genes
(e.g., from microarray expression studies) directly. Clearly,
the choice of this threshold could be arbitrary. Depending
upon the sample size and the distribution of genetic effect
sizes, a relatively stringent cutoff such as p < 0.0001 will
focus attention on SNPs most likely to be genuine associa-
tions; empirically, this worked well for CD. However, for
BD, less stringent cutoffs gave more signiﬁcant results, in
terms of overrepresented categories, the best results being
obtainedwith a cutoff of p<0.01. It is likely that the genetic
basis of complex traits will show considerable heteroge-
neity, and this is particularly true for phenotypes such as
BD, of which the diagnosis is entirely clinical and there
are currently no diagnostic tests for validation of classiﬁca-
tion.37 Most associations with individual SNPs will have
a small effect size in the sample as a whole. Thus, one of
the major aims of pathway-based analyses is detection of
pathways in which several genes show moderate associa-
tion individually. This rationale would argue for the use of
a less stringent p value criterion for selection of the list of
signiﬁcant SNPs. Clearly, there is a balance to be struck
between being conﬁdent that the associations tested are
genuine, which is greatest when a stringent cutoff is used
in deﬁning signiﬁcant SNPs, and ensuring that genuine
associations of small magnitude are not missed. It is likely
that the optimal cutoff will depend on the disease. A prag-
matic solution to the problem of choosing an arbitrary
threshold, a solution that we adopt here, is to apply a range
of cutoffs, determine which gives the most signiﬁcant
increase in overrepresented categories, and examine the
individual categories highlighted by this cutoff.9
The results for the BD meta-analysis were much more
signiﬁcant than those that would have been obtained
from analyzing the WTCCC BD sample alone (results
shown in Table S5), highlighting the importance of using
large sample sizes to give high power to detect associations
of small magnitude.
Several promising methods have recently been devel-
oped for imputing genotypes at untyped SNPs with the
use of the genotyped SNPs and the Hapmap data.40 We ex-
pected that the use of imputed SNPs might increase power
of the method, because more genes would become infor-
mative. Our analysis of the BD meta-analysis data co-
nﬁrmed that this hypothesis was correct (results obtained
when genotype data was used alone are in Table S6).
Another issue that is applicable to any method based
upon genes concerns how the boundaries of genes are
deﬁned. We used two options. First, SNPs were assigned to
genes only if they lay within the start of the ﬁrst and the
end of the last known exon. In the second approach, SNPs
mapping within 20 kb of a gene (50 or 30) were assigned to
that gene.When the optimal cutoff for selecting signiﬁcant
SNPs (p < 0.01) was used, we observed no apparent
improvement in the results by using the latter approach
(see Table S7), which was designed to capture the proximal
functional elements of most genes. The choice of 20 kb is
not entirely arbitrary—a recent study of gene expression41
found that themajority of eQTLs lay within 20 kb of genes.
However, other window sizes are also justiﬁable; for
example, a 500 kb window has been used.11 Again, there
is a balance to be struck between narrowwindows (running
the risk of missing regulatory regions) and wide regions
(increasing the chance that an associated SNP has no func-
tional relationship with the gene to which it is assigned).
It is possible to reduce the multiple-testing burden by re-
stricting analysis to a subset of GO categories; for example,
GO level 4 categories containing between 20 and 200
genes.11 Alternatively, a partitioning method42 could be
used for selection of informative subsets of categories for
analysis. However, for a disease such as BD, for which
previousbiological information is limited, there isnoapriori
indication of which size or level of category will best reﬂect
the underlying biological processes. Thus, selecting any
subset of categories for analysis risks the loss of information.
Because the aim of our study was to investigate what the
GWA results could tell us about the biological basis of BD,
while making as few assumptions as possible, we chose to
analyze all GO categories. Although our results must neces-
sarily be regarded as exploratory and do require replication
in other studies, it should be noted that we did observe an
experiment-wide excess of signiﬁcantly overrepresented
categories even after correcting for multiple categories.
A limitationofourmethod is that it counts eachgeneonly
once. If a gene contains multiple independent hits, it is
possible that counting each of these separately could
increase the power of the study. We investigated this in
the CD data by selecting a subset of 61,246 SNPs in low LD
(r2 < 0.2) lying within genes. Each signiﬁcant SNP in a GOThcategory was counted separately, and signiﬁcance of over-
representation was tested by generating random lists of
‘‘signiﬁcant’’ SNPs of the same length as the original. This
didnot increase the signiﬁcanceof the results, nordid it alter
the most signiﬁcant GO categories (see Tables S8 and S9).
One reason for thismight be that the subset of SNPs covered
fewer genes than the original SNP set (12,899 to 14,653), so
potentially important genes might have been ‘‘lost.’’ It is
possible that counting signiﬁcant SNPs in low LD separately
may increase power for some diseases, particularly if a rela-
tively lax cutoff is used in deﬁning signiﬁcance (because
this makes multiple independent signals more likely).
However, such SNPs may not be truly independent (depen-
dent on the r2 cutoff), so analyzing them as independent
may cause false-positive results. Using a stricter r2 cutoff
will reduce thispossibility, but itmay result ina lossofpower
due todecreased gene coverage. SNP selection strategies that
maximize power merit further work.
An alternative method for testing for overrepresentation
of pathways among signiﬁcant SNPs from GWA studies is
given by Wang et al.11 Their method involves ranking all
genes in order of signiﬁcance (based on association-test
statistics for individual SNPs), then comparing the distribu-
tion of ranks of genes in a particular pathway to the remain-
ing genes via a Kolmogorov-Smirnov test. This test can be
modiﬁed to take into account the actual test statistics asso-
ciatedwith the genes, withhigherweights assigned tomore
signiﬁcant genes. This is amodiﬁcation of themethod used
by theprogramGSEA.43 This approachhas the advantage of
not requiring a criterion for signiﬁcant SNPs, and genes, to
be speciﬁed, because it is based on the distribution of ranks
in the whole set of genes. However, the Kolmogorov-Smir-
nov test does not take into account where in the overall
distribution the differences in ranks lie. Thus, a signiﬁcant
result could be based on differences in rank occurring
among genes some way down the list, with nonsigniﬁcant
p values for association. Such a result would be of limited
interest. Conversely, the weighting scheme used by Wang
et al.11 favors pathways inwhich a fewgeneshave very large
test statistics in comparison to the others over pathways
with several genes of approximately similar signiﬁcance.
Asnoted above, the aimof pathway analysis is, at least argu-
ably, to detect the latter sort of pathway, given that genes
with very large test statistics will be apparent from inspec-
tion of the individual SNP p values. Perhaps a useful
compromise between these extremes would be to deﬁne
a list of SNPs, and thus genes, of interest, as in the method
proposed here, but to assign each gene a score based on its
rank within the list. For example, if the list has n genes,
assign the most signiﬁcant a score of n, the next a score of
n  1, and so on. Genes not on the list would be assigned
a score of zero. A score for each pathway could then be ob-
tained by summing the scores of its genes, and the signiﬁ-
cance of the pathway score could be tested in a manner
similar to that described here.
As noted by Wang et al.,11 ranking genes on the basis of
the most signiﬁcant SNP within each gene favors largee American Journal of Human Genetics 85, 13–24, July 10, 2009 21
genes with several SNPs, and any analysis of the signiﬁ-
cance must allow for this. Ideally, one would reanalyze
the entire genome, permuting case and control status, to
obtain sets of ranked genes to which the observed results
can be compared. Such a method allows for varying sizes
and LD structure among genes, but it is computationally
demanding, particularly if imputed data are used. Further-
more, permutation requires individual genotype data to be
available. Therefore, a single p value is assigned to each
gene by Wang et al.,11 and these are permuted randomly
among all genes. Two methods are proposed for obtaining
a single p value for each gene: (1) using the most signiﬁ-
cant p value and (2) applying a Simes correction to the
p values from that gene and using the corrected p value
in the analysis. Using the most signiﬁcant p value will
increase the chance that large genes with several SNPs
rank highly by chance, and thus it may falsely inﬂate
the signiﬁcance of pathways that contain such genes. Co-
nversely, the Simes correction will be very conservative for
large genes containing only a few highly signiﬁcant SNPs,
particularly if the analysis method for overrepresentation
uses the actual p value (as does the method used by
Wang et al.11) rather than just presence on a list of signif-
icant genes. Furthermore, applying the Simes correction
may alter the order of genes from that in the original
data, which may be undesirable when rank-based methods
are being used. Our method allows for the varying sizes of
genes by a random selection of SNPs for generation of the
replicate gene lists against which the observed data are
tested. Thus, the probability that a gene is added to the
list is proportional to the number of SNPs that it contains.
This assumes that SNPs in different genes are not in LD, so
the position of a gene on the list does not depend on that
of nearby genes. Regions of the genome that are known to
show long-range LD, such as the MHC region, will violate
this assumption. Reanalyzing the data, omitting SNPs and
genes within these regions, provides a means of checking
that signiﬁcant overrepresentation of GO categories is not
solely a result of a few genes being in LD with each other.
When the MHC region was removed, the signiﬁcance of
GO categories containing several MHC genes (such as
those involving immunological response or MHC activity)
was reduced, removing them from the list of signiﬁcant
categories in Table S3. This does not necessarily mean
that the signiﬁcantly overrepresented MHC-related cate-
gories observed in Table 2 are false positives, since multiple
hits from the MHC region could still be independent.
Indeed, the fact that the MHC-activity- and immunolog-
ical-response-related categories were the most signiﬁcant
when the LD-pruned SNP set was used (see Table S9)
suggests that multiple hits from the MHC region are not
in strong LD with each other. Careful examination of
the LD patterns between signiﬁcant SNPs would be
required for assessment of whether the multiple signiﬁ-
cant genes in the MHC region could result from the
same association signal or represent multiple distinct
signals.22 The American Journal of Human Genetics 85, 13–24, July 10, 200An additional assumption of our method is that LD
within genes is approximately constant (so that the effec-
tive number of tests per gene is roughly proportional to
the number of SNPs), but when that assumption is
violated, such as in regions of high LD, our analysis will
be conservative. It is difﬁcult to fully allow for variable
LD levels without resorting to simulation-based methods
(for which the full genotype data are required). The SNP-
pruning approach mentioned above is a possibility, but it
needs further evaluation. It should be noted, however,
that our method is only an initial stage in highlighting
interesting genes and pathways for further study and
that issues of inter-SNP LD will need to be resolved by
more detailed analyses of individual genotype data.
In summary,we detail amethod for implicating biological
pathways likely to be involved in disease susceptibility. In
a proof-of-principle application, we correctly identiﬁed
pathways known or suspected to be involved in CD. When
applied to BD, a disorder whose pathophysiology is almost
entirelyunknown, the results suggest thatbiological systems
involved inmodulationof transcriptionandcellular activity
are implicated, as is hormonal function, including thyroid
hormone. These observations suggest that a core feature of
pathogenesis of BD may be a disturbance in regulation of
transcriptional activity. Although intriguing, these results
need to be replicated in additional large studies.
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Supplemental Data include a complete list of WTCCC members
and nine tables and can be found with this article online at
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